Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Patents

The global patent landscape of HER2-targeted biologics

Nature Biotechnology volume 41, pages 756–764 (2023)Cite this article

Subjects

Global patents on HER2-targeted biologics show rapid growth and a diversified technology pattern.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Flow diagram of the data processing of the patent sample.
Fig. 2: Patent documents by publication year.
Fig. 3: Technology classes and time trends of patents.
Fig. 4: Technology flow landscape.
Fig. 5: Radar charts of amino acid classification of CDRs in HER2 mAb patents.
Fig. 6: Frequency plot of sequence logos of HER2 mAb sequences in patents.

References

  1. Lucas, L. M. et al. Pharmacol. Rev. 74, 18–47 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Pellat, A., Vaquero, J. & Fouassier, L. Hepatology 67, 762–773 (2018).

    Article  CAS  PubMed  Google Scholar 

  3. Shiau, J. P. et al. Antioxidants 11, 841 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Blangé, D., Stroes, C. I., Derks, S., Bijlsma, M. F. & van Laarhoven, H. W. M. Cancer Treat. Rev. 108, 102418 (2022).

    Article  PubMed  Google Scholar 

  5. Nabholtz, J. M., Reese, D. M., Lindsay, M. A. & Riva, A. Clin. Breast Cancer 3(Suppl. 2), S75–S79 (2002).

    Article  PubMed  Google Scholar 

  6. Maadi, H., Soheilifar, M. H., Choi, W. S., Moshtaghian, A. & Wang, Z. Cancers (Basel) 13, 3540 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Collins, D. M. et al. Ann. Oncol. 23, 1788–1795 (2012).

    Article  CAS  PubMed  Google Scholar 

  8. Harbeck, N. et al. Breast Care (Basel) 8, 49–55 (2013).

    Article  PubMed  Google Scholar 

  9. Zheng, M. et al. Acta Pharm. Sin. B 11, 2645–2654 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Robinson, A. et al. Breast Cancer Res. Treat. 178, 337–345 (2019).

    Article  CAS  PubMed  Google Scholar 

  11. Rimawi, M. et al. J. Clin. Oncol. 36, 2826–2835 (2018).

    Article  CAS  PubMed  Google Scholar 

  12. Collins, D. M. et al. Clin. Cancer Res. 27, 807–818 (2021).

    Article  CAS  PubMed  Google Scholar 

  13. Fujihara, M. et al. Int. J. Mol. Sci. 22, 12809 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Modi, S. et al. N. Engl. J. Med. 387, 9–20 (2022).

    Article  CAS  PubMed  Google Scholar 

  15. Gombos, A., Franzoi, M. A. & Awada, A. Expert Opin. Investig. Drugs 28, 617–627 (2019).

    Article  CAS  PubMed  Google Scholar 

  16. Meric-Bernstam, F. et al. Clin. Cancer Res. 25, 2033–2041 (2019).

    Article  CAS  PubMed  Google Scholar 

  17. Li, Z. et al. EBioMedicine 62, 103074 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. O’Rourke, K. Cancer 128, 938 (2022).

    PubMed  Google Scholar 

  19. Zhang, H., Katerji, H., Turner, B. M. & Hicks, D. G. Am. J. Clin. Pathol. 157, 328–336 (2022).

    Article  CAS  PubMed  Google Scholar 

  20. Zhang, X. et al. Antib. Ther. 5, 18–29 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Pernas, S. & Tolaney, S. M. Ther. Adv. Med. Oncol. 11, 1758835919833519 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lyu, L., Feng, Y., Chen, X. & Hu, Y. Nat. Biotechnol. 38, 1387–1394 (2020).

    Article  CAS  PubMed  Google Scholar 

  23. Smith, J. A. et al. Nat. Biotechnol. 36, 1043–1047 (2018).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the National Science and Technology Major project (2020ZX09201021), the National Natural Science Foundation of China project (8197247, 82273204 and 82203086), the Sun Yat-sen University Clinical Research 5010 Program (2018007), the Guangzhou Science and Technology Major Program (202206010078), the Guangzhou Science and Technology Program (202201020574 and 202201020246), the Medical Artificial Intelligence Project of Sun Yat-sen Memorial Hospital (YXRGZN201902), the CSCO-Hengrui Cancer Research Foundation (Y-HR2018-284), the Guangdong Basic and Applied Basic Research Foundation project (2020A1515110756 and 2023A1515010916), the China Postdoctoral Science Foundation (2020TQ0377 and 2020M683168), the Zhuhai UM Science & Technology Research Institute project (ZUMRI/064/2021) and the Science and Technology Development Fund, Macau SAR (SKL-QRCM(UM)-2023-2025).

Author information

Author notes

  1. These authors contributed equally: Qingjian Li, Jiaqi Xu, Qianshu Sun.

Authors and Affiliations

  1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Breast Tumor Centre, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    Qingjian Li, Zebang Zhang & Herui Yao

  2. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China

    Jiaqi Xu, Qianshu Sun & Yuanjia Hu

  3. Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Taipa, Macau, China

    Yuanjia Hu

Authors
  1. Qingjian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiaqi Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qianshu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zebang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuanjia Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Herui Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yuanjia Hu or Herui Yao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Supplementary Information

Supplementary Fig. 1 and Supplementary Tables 1–3

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Q., Xu, J., Sun, Q. et al. The global patent landscape of HER2-targeted biologics. Nat Biotechnol 41, 756–764 (2023). https://doi.org/10.1038/s41587-023-01814-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01814-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer